-
The CDC identified 17 patients with community-acquired pneumonia (CAP) due to S. aureus by following up on reports from the Emerging Infections Network of the Infectious Disease Society of America (IDSA) during the 2003-2004 influenza season.
-
The STAR Trial (Tamoxifen and Raloxifene); FDA Actions
-
In October 2005, the American Committee on Immunization Practices provided provisional recommendations for the acellular pertussis vaccine (Tdap) (ADACELTM, Sanofi Pasteur) as a single booster dose for persons 11-64 years of age.
-
Due to the long half-lives of nevirapine and efavirenz, it is now recommended that when non-nucleoside reverse transcriptase inhibitor (nnRTI)-containing antiretroviral regimens are discontinued, backbone nucleoside analogs should be continued for 4-7 days to reduce the likelihood of development of nnRTI resistance.
-
Posaconazole exhibits numerous advantages over other triazoles in regards to drug-drug interactions, bioavailability issues, and its side-effect profile.
-
The rapidly evolving epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) colonization and infection has resulted in ambiguity in the designation of individual instances as either community or health care associated. This essay represents a proposal for a telegraphic system of unambiguous description of isolates.
-
King and colleagues conducted prospective, laboratory-based surveillance of all community-onset staphylococcal skin and soft-tissue infections presenting to Grady Memorial Hospital and its affiliated clinics for a 3.5-month period in 2003.
-
That air travel is associated with increased risk of deep venous thrombosis (DVT) is well established; Obesity is a recognized risk factor for GERD; and Anti-TNF antibody (aTNFa) therapy offers significant benefit to sufferers of rheumatoid arthritis (RA).
-
The FDA has licensed a new vaccine to reduce the risk of shingles in the people 60 years of age and older.
-
Low-dose aspirin plus celecoxib led to ulcers in 19% of recipients vs 27% ulcers in patients receiving naproxen and low-dose aspirin. The group receiving low-dose aspirin plus placebo had 8% ulcer development.